Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 47Lenalidomide 31daratumumab 24Bortezomib 23pomalidomide 19carfilzomib 15Specimen Handling 15Cyclophosphamide 15Calcium Dobesilate 15Biopsy 15Magnetic Resonance Spectroscopy 11talquetamab 9isatuximab 9Melphalan 9iberdomide 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8fludarabine 7belantamab mafodotin 7selinexor 5X-Rays 5tocilizumab 4fludarabine phosphate 4elotuzumab 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Thalidomide × Plasma cell × 30 days × Clear all
NCT00602641 2026-05-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT00734877 2026-05-22

TT4B

University of Arkansas

Phase 3 Active not recruiting
382 enrolled
Plasma cell

Multiple Myeloma

NCT00869232 2026-05-22

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

University of Arkansas

Phase 2 Active not recruiting
90 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡